Silo Pharma Inc
SILO
查看详细走势图
0.306USD
+0.019+6.55%
收盘 02/06, 16:00（美东）报价延迟15分钟
3.20M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+6.55%
5天
-11.39%
1月
-19.93%
6月
-51.41%
今年开始到现在
-10.06%
1年
-81.24%
查看详细走势图
TradingKey Silo Pharma Inc股票评分
单位: USD 更新时间: 2026-02-06操作建议
Silo Pharma Inc当前公司基本面数据相对非常健康，最新ESG披露属于行业领先水平。增长潜力较大。当前估值合理，在药品行业排名124/159位。机构持股占比非常高，中期看，股价处于下降通道。近一个月，市场表现非常差，但基本面评分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Silo Pharma Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
看空
Silo Pharma Inc亮点
亮点风险
Silo Pharma, Inc. is a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company. The Company’s therapeutic focus is on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The Company’s portfolio includes programs, such as for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer’s disease and multiple sclerosis. Its lead product candidate, SPC-15, is designed as a novel serotonin 4 (5-HT4) receptor agonist that utilizes biomarkers for treatment of stress-induced psychiatric disorders such as PTSD and anxiety disorders. SPC-14 targets glutamate receptor NDMAR and serotonin 5-HT4 to address cognitive and neuropsychiatric symptoms in Alzheimer’s disease. SPU-16 is a candidate targeting central nervous system (CNS) disorders, with an initial indication for multiple sclerosis.
业绩增长期
公司处于发展阶段，最新年度总收入72.10K美元
估值高估
公司最新PE估值-0.34，处于3年历史高位
机构加仓
最新机构持股1.56M股，环比增加40.16%
先锋集团持仓
明星投资者先锋集团持仓，最新持仓市值24.32K
活跃度降低
近期活跃度降低，过去20天平均换手率-0.79
分析师目标
根据
0
位分析师
--
评级
0.000
目标均价
0.00%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Silo Pharma Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Silo Pharma Inc简介
Silo Pharma, Inc. is a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company. The Company’s therapeutic focus is on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The Company’s portfolio includes programs, such as for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer’s disease and multiple sclerosis. Its lead product candidate, SPC-15, is designed as a novel serotonin 4 (5-HT4) receptor agonist that utilizes biomarkers for treatment of stress-induced psychiatric disorders such as PTSD and anxiety disorders. SPC-14 targets glutamate receptor NDMAR and serotonin 5-HT4 to address cognitive and neuropsychiatric symptoms in Alzheimer’s disease. SPU-16 is a candidate targeting central nervous system (CNS) disorders, with an initial indication for multiple sclerosis.
公司代码SILO
公司Silo Pharma Inc
CEOWeisblum (Eric)
网址https://silopharma.com/
相关品种
